Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657054 | 0.73 | ALDH1A1 (0.50) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL1652855 | 0.71 | ALDH1A1 (0.64) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL10957985 | 0.64 | ALDH1A1 (1.00) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL6394776 | 0.60 | ALDH1A1 (0.67) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL1653731 | 0.59 | ALDH1A1 (0.65) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL3829961 | 0.59 | ALDH1A1 (0.65) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL1545990 | 0.59 | ALDH1A1 (0.75) | ALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL5403840 | 0.58 | GAA (0.45) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL5403839 | 0.58 | GAA (0.45) | ALDH1A1POLBTSHRNPSR1HSD17B10 | |
| SCHEMBL5403856 | 0.55 | ALDH1A1 (0.56) | ALDH1A1POLBTSHRNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | ALDH1A1 903/4885POLB 383/4885TSHR 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.